Market revenue in 2022 | USD 72.9 million |
Market revenue in 2030 | USD 145.8 million |
Growth rate | 9.1% (CAGR from 2022 to 2030) |
Largest segment | Innovative |
Fastest growing segment | Generic |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Innovative, Generic |
Key market players worldwide | Piramal Pharma Solutions, Lonza Group Ltd, Catalent Inc, Pfizer Inc, AbbVie Inc, Dr Reddy's Laboratories Ltd ADR, VxP Pharma, Gentec Pharmaceutical Group, CordenPharma, Curia |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to high potency api contract manufacturing market will help companies and investors design strategic landscapes.
Innovative was the largest segment with a revenue share of 72.57% in 2022. Horizon Databook has segmented the UAE high potency api contract manufacturing market based on innovative, generic covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE high potency api contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into UAE high potency api contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account